BACKGROUND: The relation between vitamin D status and lymphoma risk is inconclusive. OBJECTIVE: We examined the association between prediagnostic plasma 25-hydroxyvitamin D [25(OH)D] and lymphoid cancer risk. DESIGN: We conducted a study nested within the European Prospective Investigation into Cancer and Nutrition cohort of 1127 lymphoma cases and 1127 matched controls with a mean follow-up time of 7.1 y. Conditional logistic regression was used to estimate multivariable-adjusted incidence rate ratios of lymphoma risk in relation to plasma 25(OH)D. Season-standardized and season-specific 25(OH)D quartiles were used. We also analyzed 25(OH)D as a continuous variable and used predefined cutoffs. RESULTS: No statistically significant association between plasma 25(OH)D and overall lymphoid cancer risk was observed. A positive association for B-cell non-Hodgkin lymphoma was noted only in those with a diagnosis made during the first 2 y of follow-up (P-heterogeneity = 0.03), which suggests the possibility of reverse causality. Further analysis restricted to participants with ≥2 y of follow-up time showed a significant association between 25(OH)D and chronic lymphocytic leukemia (CLL) (n = 161): adjusted incidence rate ratios were 0.40 (95% CI: 0.18, 0.90; P-trend = 0.05) and 0.31 (95% CI: 0.13, 0.76; P-trend = 0.03) for the top compared with the bottom season-standardized and season-specific quartiles, respectively. Data on dietary vitamin D intake provided further support for the observed association (incidence rate ratio: 0.33; 95% CI = 0.12, 0.89; P-trend = 0.006). CONCLUSIONS: Our findings do not support a protective role of high 25(OH)D concentration in lymphoid cancers overall. However, they suggest that higher concentrations of 25(OH)D are associated with a reduced risk of CLL.
BACKGROUND: The relation between vitamin D status and lymphoma risk is inconclusive. OBJECTIVE: We examined the association between prediagnostic plasma 25-hydroxyvitamin D [25(OH)D] and lymphoid cancer risk. DESIGN: We conducted a study nested within the European Prospective Investigation into Cancer and Nutrition cohort of 1127 lymphoma cases and 1127 matched controls with a mean follow-up time of 7.1 y. Conditional logistic regression was used to estimate multivariable-adjusted incidence rate ratios of lymphoma risk in relation to plasma 25(OH)D. Season-standardized and season-specific 25(OH)D quartiles were used. We also analyzed 25(OH)D as a continuous variable and used predefined cutoffs. RESULTS: No statistically significant association between plasma 25(OH)D and overall lymphoid cancer risk was observed. A positive association for B-cell non-Hodgkin lymphoma was noted only in those with a diagnosis made during the first 2 y of follow-up (P-heterogeneity = 0.03), which suggests the possibility of reverse causality. Further analysis restricted to participants with ≥2 y of follow-up time showed a significant association between 25(OH)D and chronic lymphocytic leukemia (CLL) (n = 161): adjusted incidence rate ratios were 0.40 (95% CI: 0.18, 0.90; P-trend = 0.05) and 0.31 (95% CI: 0.13, 0.76; P-trend = 0.03) for the top compared with the bottom season-standardized and season-specific quartiles, respectively. Data on dietary vitamin D intake provided further support for the observed association (incidence rate ratio: 0.33; 95% CI = 0.12, 0.89; P-trend = 0.006). CONCLUSIONS: Our findings do not support a protective role of high 25(OH)D concentration in lymphoid cancers overall. However, they suggest that higher concentrations of 25(OH)D are associated with a reduced risk of CLL.
Authors: José Manuel Ordóñez-Mena; Ben Schöttker; Veronika Fedirko; Mazda Jenab; Anja Olsen; Jytte Halkjær; Ellen Kampman; Lisette de Groot; Eugene Jansen; H Bas Bueno-de-Mesquita; Petra H Peeters; Galatios Siganos; Tom Wilsgaard; Laura Perna; Bernd Holleczek; Ulrika Pettersson-Kymmer; Philippos Orfanos; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: Eur J Epidemiol Date: 2015-05-15 Impact factor: 8.082
Authors: Elizabeth K Cahoon; Ruth M Pfeiffer; David C Wheeler; Juan Arhancet; Shih-Wen Lin; Bruce H Alexander; Martha S Linet; D Michal Freedman Journal: Int J Cancer Date: 2014-10-13 Impact factor: 7.396
Authors: Jennifer L Kelly; Gilles Salles; Bryan Goldman; Richard I Fisher; Pauline Brice; Oliver Press; Olivier Casasnovas; David G Maloney; Pierre Soubeyran; Lisa Rimsza; Corinne Haioun; Luc Xerri; Michael LeBlanc; Hervé Tilly; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Paige M Kulling; Kristine C Olson; Thomas L Olson; David J Feith; Thomas P Loughran Journal: Eur J Haematol Date: 2016-11-21 Impact factor: 2.997
Authors: Aurora Perez-Cornago; Paul N Appleby; Sarah Tipper; Timothy J Key; Naomi E Allen; Alexandra Nieters; Roel Vermeulen; Sandrine Roulland; Delphine Casabonne; Rudolf Kaaks; Renee T Fortner; Heiner Boeing; Antonia Trichopoulou; Carlo La Vecchia; Eleni Klinaki; Louise Hansen; Anne Tjønneland; Fabrice Bonnet; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Valeria Pala; Giovanna Masala; Carlotta Sacerdote; Petra H Peeters; H B As Bueno-de-Mesquita; Elisabete Weiderpass; Miren Dorronsoro; J Ramón Quirós; Aurelio Barricarte; Diana Gavrila; Antonio Agudo; Signe Borgquist; Ann H Rosendahl; Beatrice Melin; Nick Wareham; Kay-Tee Khaw; Marc Gunter; Elio Riboli; Paolo Vineis; Ruth C Travis Journal: Int J Cancer Date: 2016-12-27 Impact factor: 7.396
Authors: Emily M Bowen; Ruth M Pfeiffer; Martha S Linet; Wayne T Liu; Dennis D Weisenburger; D Michal Freedman; Elizabeth K Cahoon Journal: Br J Cancer Date: 2016-02-18 Impact factor: 7.640